openPR Logo
Press release

Investigation announced for Investors in shares of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) over possible Violations of Securities Laws

09-14-2022 03:01 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) shares over potential securities laws violations b

An investigation for investors in Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) shares over potential securities laws violations b

An investigation was announced over potential securities laws violations by Eiger BioPharmaceuticals, Inc. in connection with certain financial statements.

Investors who purchased shares of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Eiger BioPharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Palo Alto, CA based Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally.

On September 6, 2022, Eiger BioPharmaceuticals, Inc. provided an update on the status of its planned request for emergency use authorization (EUA) of peginterferon lambda. Following a cooperative and extensive pre-EUA information exchange with FDA regarding the Phase 3 TOGETHER study of peginterferon lambda for COVID-19, the agency has indicated that it is not yet able to determine whether the criteria for the submission of an application and issuance of an EUA are likely to be met. FDA has indicated that it will consider any new information and data from the TOGETHER study to support a EUA as well as the company's plans for the further development of peginterferon lambda for COVID-19. Eiger BioPharmaceuticals, Inc. said that it remains in active dialogue with FDA and will provide additional information to the agency that the company believes could be supportive of a EUA.

Shares of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) declined from $9.89 per share on August 16, 2022, to as low as $5.84 per share on September 06, 2022.

Those who purchased shares of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) over possible Violations of Securities Laws here

News-ID: 2733492 • Views: 239

More Releases from Shareholders Foundation

Investigation announced for Investors who lost Money with their shares in Roblox …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Roblox Corporation. Investors who purchased shares of Roblox Corporation (NYSE: RBLX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Roblox directors breached their fiduciary duties and caused damage to the company and its shareholders. San Mateo, CA based Roblox Corporation develops
Investigation announced for Investors in Waterdrop Inc. (NYSE: WDH) over possibl …
An investigation was announced over potential securities laws violations by Waterdrop Inc. in connection with certain financial statements. Investors who purchased shares of Waterdrop Inc. (NYSE: WDH), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Waterdrop Inc. (NYSE: WDH regarding its business, its prospects and its operations were materially
Sinovac Biotech Ltd. (formerly NASDAQ: SVA) Investor Notice: Deadline in Lawsuit …
A deadline is coming up on October 17, 2022 in the lawsuit filed for certain investors of Sinovac Biotech Ltd. (formerly NASDAQ: SVA) over alleged securities laws violations by Sinovac Biotech Ltd. Investors who purchased shares of Sinovac Biotech Ltd. (formerly NASDAQ: SVA) have certain options and there are strict and short deadlines running. Deadline: October 17, 2022. Sinovac Biotech Ltd. (formerly NASDAQ: SVA) stockholders should contact the Shareholders Foundation at
Investigation announced for Investors in Anaplan, Inc. (NYSE: PLAN) over potenti …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Anaplan, Inc. Investors who are current long term investors in Anaplan, Inc. (NYSE: PLAN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: PLAN stocks follows a lawsuit filed against Anaplan, Inc. over

All 5 Releases